fig1
Figure 1. Predictive biomarkers of gastric cancer immunotherapy. PD-L1: Programmed cell death-ligand 1; TMB: tumor mutation burden; MSI-H: microsatellite instability-high; dMMR: mismatch repair deficiency; EBV: Epstein-Barr virus; ctDNA: circulating tumor DNA; EVs: extracellular vesicles; irAEs: immune-related adverse events; TME: tumor microenvironment.
